FUS Protein-Targeting Therapy for ALS/FTD

Overview

This therapeutic approach targets FUS (Fused in Sarcoma) proteinopathy, a core pathology in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). FUS is an RNA-binding protein that normally resides in the nucleus but mislocalizes to cytoplasmic inclusions in a subset of ALS and FTD cases. This approach combines RNA-targeting strategies with proteostasis enhancement to reduce toxic FUS aggregates and restore nuclear function.

Mechanism of Action

Pathological Context

FUS is a 526-amino acid RNA-binding protein involved in RNA splicing, transport, and DNA repair. In ~5-10% of ALS cases and ~10% of FTD cases, FUS accumulates in cytoplasmic inclusions alongside TDP-43 pathology^{1Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis2009 · Science · PMID 19350693Open reference2Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 62009 · Science · PMID 19350694Open reference}. Mutations in the FUS gene (ALS6 locus) cause familial ALS, demonstrating that FUS dysfunction is disease-causing.

Key pathological features:

• Nuclear export dysregulation: FUS mutations impair nuclear localization signals (NLS), leading to cytoplasmic accumulation^{3ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import2010 · EMBO Journal · PMID 20168091Open reference}

• Liquid-liquid phase separation failure: Disease mutations disrupt FUS liquid-liquid phase separation (LLPS), promoting solid aggregate formation^{4ALS-associated FUS mutations lead to mechanical cracking of RNA stress granules2016 · Nature · PMID 27845388Open reference5Structure of FUS protein fibrils and its relevance to self-assembly and phase separation2018 · Cell · PMID 29420199Open reference}

• RNA metabolism disruption: Cytoplasmic FUS sequesters RNA and mRNA transport proteins

• Stress granule persistence: FUS-positive stress granules persist instead of dissolving, becoming toxic aggregates^{6Cytoplasmic accumulation of FUS in motor neurons is sufficient to cause ALS-like phenotypes in mice2016 · Acta Neuropathologica · PMID 26555377Open reference7Stress granules in ALS and FTD: emerging mechanistic insights2016 · Journal of Pathology · PMID 27343457Open reference}

Therapeutic Strategy

Primary Mechanism: Reduce FUS expression using RNA-targeting approaches (ASO, RNAi) or enhance FUS clearance through autophagy enhancement.

Secondary Mechanism: Target stress granule dynamics using small molecules that promote granule dissolution without blocking protective stress response.

Tertiary Mechanism: Nuclear import enhancement using nuclear localization signal (NLS) peptide conjugates or small molecule nuclear import enhancers.

Rubric Scores

Dimension	Score	Rationale
Novelty	9	First-in-class mechanism targeting FUS proteinopathy distinct from TDP-43 approaches
Mechanistic Rationale	8	Strong genetic evidence (FUS mutations cause ALS6), pathology confirmed in sporadic cases
Addresses Root Cause	8	Targets protein aggregation at source rather than downstream effects
Delivery Feasibility	6	CNS delivery achievable via intrathecal ASO (proven in other ALS programs)
Safety Plausibility	7	Allele-specific targeting possible for mutant FUS sparing wild-type function
Combinability	8	Synergistic with TDP-43 targeted therapies, autophagy enhancers
Biomarker Availability	7	CSF FUS levels, pNfH as neurodegeneration marker, FUS PET ligands in development
De-risking Path	7	iPSC-derived neurons from FUS-ALS patients, FUS transgenic mouse models exist
Multi-disease Potential	8	ALS, FTD, and rare FUS-linked encephalopathies
Patient Impact	8	Addresses rapidly progressive motor neuron disease with high unmet need

Total Score: 76/100

Preclinical Evidence

Genetic Evidence

• FUS mutations cause ALS6 (autosomal dominant): P525L, R521C, R521H, R522G^{1Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis2009 · Science · PMID 19350693Open reference2Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 62009 · Science · PMID 19350694Open reference}

• FUS inclusions found in 5-10% of sporadic ALS cases

• FUS-FTD represents ~10% of all FTD cases

Preclinical Models

• FUS-ALS iPSC models: Motor neurons show cytoplasmic FUS mislocalization, stress granule persistence, and axonal transport defects^{6Cytoplasmic accumulation of FUS in motor neurons is sufficient to cause ALS-like phenotypes in mice2016 · Acta Neuropathologica · PMID 26555377Open reference}

• Transgenic mice: FUS P525L knock-in mice develop ALS phenotype with FUS inclusions^{2Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 62009 · Science · PMID 19350694Open reference}0

• Cell models: FUS LLPS mutants show accelerated aggregation and reduced dissolution^{2Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 62009 · Science · PMID 19350694Open reference}1^{2Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 62009 · Science · PMID 19350694Open reference}2

Small Molecule Screening

• Stress granule modulators: Several compounds identified that promote stress granule dissolution

• Autophagy enhancers: Rapamycin, TFEB activators enhance FUS aggregate clearance in cellular models

Development Pathway

Phase 1: Target Validation (Months 1-12)

• Validate FUS as therapeutic target in patient-derived iPSC neurons

• Confirm allele-specific ASO approach feasibility

• Develop CSF biomarker for target engagement

• Go/No-Go: Demonstrate >50% FUS reduction without toxicity

Phase 2: Preclinical Development (Months 10-24)

• Lead ASO optimization for CNS delivery

• GLP toxicology in non-human primates

• Biomarker assay validation

• IND-enabling studies

• Go/No-Go: Positive GLP toxicology, biomarker assay qualified

Phase 3: Clinical Development (Months 24-48)

• Phase 1 safety in healthy volunteers (if applicable)

• Phase 2 dose-finding in FUS-ALS/FTD patients

• Biomarker validation for patient enrichment

• Go/No-Go: Clear target engagement signal, acceptable safety

Phase 3b: Pivotal (Months 48-72)

• Registrational trial in FUS-ALS

• Parallel FTD cohort expansion

• Accelerated approval based on biomarker endpoints

Implementation Roadmap

Phase	Timeline	Cost	Key Milestones
Phase 1	12 months	$3-5M	Target validation, lead identification
Phase 2	14 months	$8-15M	IND-enabling studies, GLP toxicology
Phase 3	24 months	$25-40M	Clinical trials, registration
Total	50 months	$36-60M

Academic Centers

• University of Michigan (FUS-ALS expertise, Dr. Eva Feldman)

• University of Massachusetts (ALS research, Dr. Robert Brown)

• Stanford University (FTD research, Dr. Michael Greicius)

• University College London (Motor Neuron Disease Centre)

Company Partnership Opportunities

1. Ionis Pharmaceuticals — ASO platform, existing ALS programs (tofersen for SOD1)

2. Biogen — CNS delivery expertise, ALS franchise

3. Ribon Therapeutics — Stress granule biology expertise

4. Prothelia — Rare disease focus, FUS biology

Actionable Next Steps

Lab Experiments

1. Test allele-specific ASOs in FUS-ALS patient iPSC-derived motor neurons

2. Screen stress granule modulators for FUS clearance efficacy

3. Validate autophagy enhancement strategies (TFEB activation, rapamycin)

4. Develop FUS PET ligand for patient stratification

Clinical Protocol Design

1. Patient Population: FUS mutation carriers, sporadic ALS with FUS pathology

2. Enrichment Strategy: CSF FUS levels, genetic testing for FUS mutations

3. Dose-Finding Design: Bayesian adaptive design with biomarker endpoints

4. Endpoints: ALSFRS-R, CSF biomarkers, survival

Company Partnerships

1. Ionis: Leverage ASO platform, discuss FUS program option

2. Biogen: Explore partnership for clinical development

3. Roche: Discuss potential collaboration on FTD indication

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

External Links

• PubMed

• KEGG Pathways

Related Pages

• Amyotrophic Lateral Sclerosis

• Frontotemporal Dementia

• FUS Gene

• TDP

• Stress Granules

• Molecular Glue for TDP

• C9orf72 RNA

Cross-Links

• ALS Treatment Pipeline

• RNA

• Proteostasis Enhancement